|Day Low/High||75.21 / 77.17|
|52 Wk Low/High||62.66 / 94.98|
This discounted value and the potential benefits of the merger/integration catalyst is why we continue view this stock as a hold despite its recent struggles.
Jim Cramer says there are plenty of senior growth companies that can still move higher.
Right now, AbbVie is the best way to capitalize on the moment and on the future.
Jim Cramer says that, above all else, the thing you really need to be a great investor is good judgment.
This strong beat and raise result should spark renewed buying interest in the stock.
ABBV stock is still around our average cost basis price, and with GS we believe there is justification to buy back the remaining 25 shares we previously sold higher.
It is disheartening to see a new litigation headline pop up, but we do not expect this risk to have the staying power of talc and opioids.
- Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases
We like AbbVie down here because we think the Allergan deal puts AbbVie's back in control of its own destiny.
We exited one position, initiated another and upgraded several names last week.
A volatile week ends with heightened expectations for at least one more rate cut from the Fed.
Jim discusses Disney and the Disney+, Goldman Sachs, Johnson & Johnson, PepsiCo ahead of Thursday's earnings, and much more!
With the market expected to continue Tuesday's weak ISM PMI-driven woes, we are in position to do some buying at newly discounted prices.
Typically we try and stay away from adding to a position twice in one day, but we see today's selloff in AbbVie intensifying along with the broader market.
Jim discusses this morning's Amgen-AbbVie swap, UnitedHealth Group, and more!
While this marks the 125th consecutive month of expansion in the overall economy, it was the second straight month of contraction in the manufacturing sector.
We'll be using our Amgen funds to directly finance a purchase in AbbVie.
We see fewer pathways and catalysts that will get AMGN stock higher, and are downgrading our rating to a THREE, looking to sell into strength.
DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
- MAVYRET® (glecaprevir/pibrentasvir) is now available as the only 8-week pan-genotypic treatment option for treatment-naïve chronic hepatitis C (HCV) patients, without cirrhosis or with compensated cirrhosis* †
There are several reasons to consider investing in dividend stocks. Dividend investing can provide investors with a steady source of income and price appreciation.
- Final data from Phase 1b study evaluating subcutaneous infusion of investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD) to be presented as late breaker
Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.